Skip to content

Study · Ex vivo tissue · 2001

4 results

Identification, characterization, and biological activity of specific receptors for natural (ghrelin) and synthetic growth hormone secretagogues and analogs in human breast carcinomas and cell lines.

Cassoni P, Papotti M, Ghè C, Catapano F, Sapino A, Graziani A, Deghenghi R, Reissmann T, Ghigo E, Muccioli G

The Journal of clinical endocrinology and metabolism1 Apr 2001Cited by 232 (Europe PMC)

PMID11297611 (opens in a new tab)DOI10.1210/jcem.86.4.7402 (opens in a new tab)PepBankPUB-11297611
Source linkPubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabEx vivo tissueActivity measurement

    In membranes from human breast carcinomas, unlabeled hexarelin displaced bound [(125)I]-Tyr-Ala-hexarelin.

    In plain wordsIn lab tests on human breast tumour membranes, hexarelin competed for the same binding sites as a labelled hexarelin analogue.

    Peptide
    Hexarelin
    Outcome
    Not applicableDisplacement of radioligand binding
    Study

    humann: not reported in source

    Human breast carcinoma membranes
    Outcome group
    Receptor activity and mechanism · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    [(125)I]-Tyr-Ala-hexarelin bound to tumor membranes was displaced by different unlabeled GHS such as hexarelin, Tyr-Ala-hexarelin, human ghrelin, and MK-0677 as well as by desoctanoyl-ghrelin and hexarelin derivative EP-80317, which are devoid of GH-releasing properties in vivo.
    1 context sentence
    Summary · context
    The presence of specific GHS-Rs has now been investigated in nontumoral and neoplastic human breast tissue using a radioiodinated peptidyl GHS ([(125)I]-Tyr-Ala-hexarelin) as ligand.
  2. 02LabIn vitro (cells)Efficacy outcome

    In human breast carcinoma cell lines, hexarelin caused a significant inhibition of cell proliferation at concentrations close to its binding affinity.

    In plain wordsIn lab tests on human breast cancer cell lines, hexarelin slowed cell growth.

    Peptide
    Hexarelin
    Outcome
    DecreaseCell proliferation
    Study

    humann: not reported in source

    MCF7, T47D and MDA-MB231 breast carcinoma cell lines
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In these cell lines, ghrelin (as well as hexarelin, MK-0677, EP-80317, and even desoctanoyl ghrelin) caused a significant inhibition of cell proliferation at concentrations close to their binding affinity.
    1 context sentence
    Summary · context
    The presence of specific GHS binding sites was also demonstrated in three different human breast carcinoma cell lines (MCF7, T47D, and MDA-MB231), in which, surprisingly, no messenger RNA for GHS-R1a was demonstrated by RT-PCR.
  3. 03LabIn vitro (cells)Efficacy outcome

    In human breast carcinoma cell lines, MK-0677 significantly inhibited cell proliferation at concentrations close to its binding affinity.

    In plain wordsIn cells from human breast cancer, MK-0677 significantly reduced cell proliferation.

    Peptide
    MK-677 (ibutamoren)
    Outcome
    DecreaseCell proliferation
    Study

    humann: not reported in source

    MCF7, T47D, and MDA-MB231 human breast carcinoma cell lines
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In these cell lines, ghrelin (as well as hexarelin, MK-0677, EP-80317, and even desoctanoyl ghrelin) caused a significant inhibition of cell proliferation at concentrations close to their binding affinity.
    1 context sentence
    Summary · context
    The presence of specific GHS binding sites was also demonstrated in three different human breast carcinoma cell lines (MCF7, T47D, and MDA-MB231), in which, surprisingly, no messenger RNA for GHS-R1a was demonstrated by RT-PCR.
  4. 04LabIn vitro (cell-free)Activity measurement

    In human breast carcinoma membranes, MK-0677 displaced bound radiolabeled Tyr-Ala-hexarelin.

    In plain wordsIn lab tests with human breast cancer membranes, MK-0677 displaced the bound radiolabeled tracer.

    Peptide
    MK-677 (ibutamoren)
    Outcome
    Not applicableRadioligand displacement
    Study

    humann: not reported in source

    Human breast carcinoma membranes
    Outcome group
    Receptor activity and mechanism · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    [(125)I]-Tyr-Ala-hexarelin bound to tumor membranes was displaced by different unlabeled GHS such as hexarelin, Tyr-Ala-hexarelin, human ghrelin, and MK-0677 as well as by desoctanoyl-ghrelin and hexarelin derivative EP-80317, which are devoid of GH-releasing properties in vivo.
    1 context sentence
    Summary · context
    The presence of specific GHS-Rs has now been investigated in nontumoral and neoplastic human breast tissue using a radioiodinated peptidyl GHS ([(125)I]-Tyr-Ala-hexarelin) as ligand.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    14 Oct 2026, 01:46 UTC

    Study data updated · source update from Europe PMC

  2. Version 2

    13 Oct 2026, 21:44 UTC

    Study results updated

  3. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.